In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia

Anti-Cancer Drugs

Volumn 13, Issue 7, 2002, Pages 735-742

  Frost, Britt Marie ^a   Lonnerholm G ^a   Nygren, P ^a   Larsson, R ^a   Lindhagen, E ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticancer drug; Childhood leukemia; CHS 828; Cytotoxicity assay; Drug development

Indexed keywords

CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; MELPHALAN; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' 4 PYRIDYLGUANIDINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYANIDE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; GUANIDINE DERIVATIVE; N (6 CHLOROPHENOXYHEXYL) N'' CYANO N'' 4 PYRIDYLGUANIDINE; N-(6-CHLOROPHENOXYHEXYL)-N''-CYANO-N''-4-PYRIDYLGUANIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENTIATION; FEMALE; FLUOROMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION; ACUTE DISEASE; BONE MARROW CELL; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; LEUKEMIA; MYELOID LEUKEMIA; PATHOLOGY; PRESCHOOL CHILD; SEXUAL DEVELOPMENT; SURVIVAL;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; CHILD; CHILD, PRESCHOOL; CYANIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; GUANIDINES; HUMAN; INDICATORS AND REAGENTS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MALE; SEX CHARACTERISTICS; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; HUMANS;

EID: 0036667881     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200208000-00008     Document Type: Article

References (27)

1. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: Best outcome in girls infants and children with Down's syndrome
2. Acute lymphoblastic leukemia
3. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis especially in non-high-risk patients: The Nordic experience of 2648 patients diagnosed between 1981 and 1996
4. CHS 828 a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo
5. Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro
6. A phase I safety study of CHS 828 in patients with solid tumor malignancy
7. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic
8. Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: Results with 8-chloro-cAMP
9. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients
10. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients
11. In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA)
12. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia
13. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA)
14. Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells
15. Synergistic interaction of anticancer agents: A cellular perspective
16. In vitro synergistic activity of PDN-IFN alpha and NM + IFN alpha combinations on fresh bone-marrow samples from multiple myeloma patients
17. A population-based study of 272 children with acute myeloid leukaemia
18. Cellular drug resistance profiles in childhood acute myeloid leukemia: Differences between FAB types and comparison with acute lymphoblastic leukemia
19. Cell death with atypical features induced by the novel antitumoral drug CHS 828 in human U-937 GTB cells
20. Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells
21. Characteristics of etoposide-induced apoptotic cell death in the U-937 human lymphoma cell line
22. Early stimulation of acidification rate by novel cytotoxic pyridyl cyanoguanidines in human tumor cells: Comparison with m-iodobenzylguanidine
23. Guanidino-containing drugs in cancer chemotherapy: Biochemical and clinical pharmacology
24. Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro
25. Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary
26. Results of intensive therapy in childhood acute myeloid leukemia incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission
27. High dose melphalan and total body irradiation with autologous marrow rescue in childhood acute lymphoblastic leukaemia after relapse